Loading
XPORT-EC-042 tested maintenance selinexor against placebo in TP53-normal advanced endometrial cancer after response to platinum chemotherapy, chasing a subgroup finding from the earlier SIENDO trial. It missed its primary endpoint in July 2026: a trend favoured selinexor but did not reach statistical significance, a lesson in the limits of post-hoc biomarker subgroups.
The primary PFS endpoint was not met (topline 30 July 2026). A trend favoured selinexor in the modified intent-to-treat population (median PFS 12.75 vs 7.43 months), consistent with the SIENDO exploratory subgroup that motivated the trial, but not statistically significant. Karyopharm cut its endometrial investment. A lesson in the limits of post-hoc biomarker subgroups.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares TP53 and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.